Print page content Print
Increase text size Decrease text size
Text Size
APOQUELAPOQUEL

The road to itch relief felt like a long one, until APOQUEL

TRUSTED FOR OVER 6 YEARS

APOQUEL® (oclacitinib tablet) has been prescribed to more than 8 million dogs in need of fast and effective allergic itch relief.1,2

THE BENEFITS OF APOQUEL
Apoquel (oclacitinib)Apoquel (oclacitinib)
CHANGING THE COURSE
OF ALLERGIC ITCH TREATMENT
Apoquel (oclacitinib)

EFFICACY

Fast and effective

APOQUEL is the #1 prescribed medicine for allergic itch3

Effective for flea allergy, food allergy, contact allergy, atopic dermatitis4,5

Effective for fleas, food allergy, contact allergy and atopic dermatitis

APOQUEL delivered fast relief that began to control itch within 4 hours, comparable to oral steroids, in dogs with allergic dermatitis6,7

Apoquel delivered fast relief vs steroids

*The dose of prednisolone was lowered at Day 6 to account for the real-world dosing scenario of prednisolone.

APOQUEL exhibited faster onset of relief than AtopicaTM (cyclosporine capsules, USP) in the control of pruritus in dogs with atopic dermatitis8,9

Apoquel delivered fast relief vs Atopica

Atopica is a trademark of Eli Lilly and Company, its subsidiaries or affiliates.

APOQUEL demonstrated a significant reduction in inflammation over the long term10,11

Apoquel reduces skin inflammation in dogs

In a study, APOQUEL was shown to be as effective as steroids in reducing skin inflammation at all time points6,7

Apoquel is as effective as steroids at all time points

Multiple studies have demonstrated the anti-inflammatory effects of APOQUEL through its fast and significant reduction of allergic and atopic dermatitis6,7,11,12

Real-world results13

Marley

Boston Terrier Mix,
age 5, 30 lb

Marley before and after Apoquel
Marley before and after Apoquel

DIAGNOSTIC TESTING

Allows diagnostic testing

The first step in providing allergic itch relief during diagnostic testing14

APOQUEL lets you establish and maintain allergic itch relief while allowing you to achieve a diagnosis

  • Fast itch control improves quality of life14 while you conduct diagnostic trials
  • Short half-life lets you "turn-on" and "turn-off" itch control during flea control and food trials

Relieve allergic itch with APOQUEL during an 8-week15 food trial

NOT A STEROID

APOQUEL is not a steroid

First medicine specifically designed to target canine allergic itch and inflammation16,17

Works differently from steroids and cyclosporine17-19

  • Nonsteroidal APOQUEL targets specific cytokines that cause itch and inflammation, relieving symptoms of allergic skin disease with minimal impact on the immune system

Dog in fieldDog in field

Cytokines involved in dog allergies

APOQUEL inhibits the function of a variety of pruritogenic and proinflammatory cytokines, including JAK1- and JAK3-dependent cytokines involved in dog allergies…

Minimal effect on JAK-2 cytokines

…while having only minimal effect on JAK2-dependent cytokines involved in hematopoiesis and innate immunity

Apoquel (oclacitinib)

Short-term steroid use can cause side effects

  • 55% of dog owners report side effects with steroids. The most common include20:
    - Excessive thirst and urination
    - Increased hunger and appetite

  • APOQUEL works differently than steroids.17,18 Side effects reported most often are vomiting and diarrhea4

  • Balancing the need for relief with the consideration of side effects can create an emotional roller coaster for pet owners

SAFETY

The safety profile of APOQUEL is supported by pharmacovigilance data over 5 years

The overall adverse reactions incidence rate during a 5-year review is rare (more than 1 but less than 10 animals reacting per 10,000 treatments administered)21,22*

  • The incidence rate of the most commonly reported individual adverse reactions (in decreasing order: vomiting, diarrhea, lethargy, anorexia and bloodwork changes) associated with the use of APOQUEL was very rare (less than 1 dog out of 10,000 treated)22
  • Results are consistent with pre-approval pivotal safety and efficacy studies. APOQUEL is performing as expected under field conditions21,22

Safe to use in dogs 12 months of age and older

Side effects were similar to placebo over short term

  • Most common side effects in a short-term clinical trial included vomiting and diarrhea and were self-limiting4

Can be used long term for maintenance therapy

Can be used concomitantly with many medications, including NSAIDs, anti-infectives, parasiticides, antifungals and allergen-specific immunotherapy23

  • The use of APOQUEL has not been evaluated in combination with other systemic immunosuppressants, such as corticosteroids and cyclosporine

Not for use in dogs with serious infections or for use in breeding, pregnant or lactating dogs

*Rare is defined as more than 1 but less than 10 animals reacting per 10,000 treatments administered; very rare is defined as less than 1 animal reacting per 10,000 treatments administered. Reported incidence rate (calculated) is an estimated rate. Includes all ARs regardless of whether the product was administered per label directions, concomitantly or if a potential causal relationship existed.22

DOSING

How to dose APOQUEL

  • The dose of APOQUEL tablets is 0.18 to 0.27 mg/lb (0.4 to 0.6 mg/kg)
  • APOQUEL should be given twice daily (BID) for up to 14 days of therapy and once daily (SID) thereafter for maintenance
  • APOQUEL may be given with or without food
  • APOQUEL may be discontinued without tapering

DOSING GUIDE

Apoquel dose chart

SUCCESS STORIES

APOQUEL is #1 in veterinarian and pet owner satisfaction24,25

Veterinarians feel confident when prescribing APOQUEL26

“APOQUEL is a reliable, fast-acting way to ensure the pet finds relief from itching.”

— Dr Holly Dutton,
North Bay Animal Hospital, FL

“APOQUEL works well to provide relief, increasing owners' confidence in our recommendation and building trust that we are going to help their pets.”

— Dr Samantha Lockwood,
Dermatology for Animals, AZ

“Whenever you solve a problem for a pet owner, it always results in increased trust and more acceptance of other recommendations.”

— Dr Farid Saleh,
Erlich Animal Hospital, FL

Pet owners are highly satisfied with APOQUEL treatment for their dogs27

90% would recommend APOQUEL to a friend

96% believed APOQUEL improved the quality of their dog’s life

94% said APOQUEL improved the quality of their own life

APOQUEL has changed the lives of dogs and their owners!28

Hear what your peers have to say about APOQUEL!

THE BENEFITS OF APOQUEL
Apoquel (oclacitinib)Apoquel (oclacitinib)
CHANGING THE COURSE
OF ALLERGIC ITCH TREATMENT
Apoquel (oclacitinib)

*Based on survey data from veterinarians (n=250) and pet owners (n=150).

RESOURCES

APOQUEL Resources

APOQUEL is now a part of Zoetis Petcare Rewards

Clients can earn money for future veterinary visits with Zoetis Petcare Rewards. With every APOQUEL purchase, pet owners can earn rewards! Rewards can help pay for any product or service at your veterinary practice. Clients can spend their rewards on anything they choose at the veterinary office for their pet’s care.

LEARN MORE

Clinical resources

APOQUEL dosing guide

Save the APOQUEL dosing table to use in your practice

APOQUEL technical monograph

A comprehensive overview of allergic skin disease and APOQUEL, including pharmacology and clinical trials

Steroid side effects one-pager

A simple diagram that reviews short- and long-term side effects of steroids

Promotional resources

Waiting room video

Look who's talking in the APOQUEL commercial!

Download and share this video with pet owners in your waiting room

DOWNLOAD68 mb
Customize APOQUEL commercial

Customize the APOQUEL commercial

Pet owners put can put their own dogs in the APOQUEL TV commercial via this app to share on their social media.

LEARN MORE

Client information sheet

Clinical information sheet

Gives dog owners a quick overview of allergic skin disease and a review of APOQUEL treatment, explaining what to expect

Itch tracker

Helps your clients track the improvement in their dog’s itch

Pet owner brochure

An informative review of APOQUEL for your customers; can be used in the waiting room or given to owners whose dogs have been prescribed APOQUEL

INDICATIONS
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION
Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.
For more information, please see the full Prescribing Information.

INDICATIONS
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION
Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.
For more information, please see the full Prescribing Information.

References: 1. Data on file, 2014-2018 Apoquel Brand Health, 2019, Zoetis Inc. 2. Data on file, Unique Patient Count from Launch, 2020, Zoetis Inc. 3. Data on file, Monthly VetStreet Report, December 2018, Zoetis Inc. 4. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114. doi:10.1111/vde.12047. 5. Moriello KA. Canine allergic dermatitis: pathogenesis, clinical signs, and diagnosis. DVM 360. May 31, 2006. Accessed June 29, 2020. https://www.dvm360.com/view/canine-allergic-dermatitis-pathogenesis-clinical-signs-and-diagnosis. 6. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-e86. doi:10.1111/vde.12166. 7. Data on file, Study Report No. A161R-AU-12-096, Zoetis Inc. 8. Little PR, King VL, Davis KR, et al. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26(1):23-e8. doi:10.1111/vde.12186. 9. Data on file, Study Report No. 6962R-14-10-025, Zoetis Inc. 10. Data on file, Study Report No. 1962C-60-10-A16, Zoetis Inc. 11. Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (APOQUEL®) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587-e142. doi:10.1111/vde.12088. 12. Data on file, Study Report No. 1962C-60-09-930, Zoetis Inc. 13. Data on file, Pet Owner Case Study–Marley, Zoetis Inc. 14. Aleo MM, Galvan EA, Fleck TJ, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297. 15. Olivry T, Mueller RS, Prélaud P, et al. Critically appraised topic on adverse food reactions of companion animals (1): duration of elimination diets. BMC Vet Res. 2015;11:225. doi:10.1186/s12917-015-0541-3. 16. Data on file, Press Release, 2014, Zoetis Inc. 17. Gonzales AJ, Bowman JW, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324. doi:10.1111/jvp.12101. 18. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2-13. doi:10.1016/j.mce.2010.04.005. 19. Guaguère E, Steffan J, Olivry T. Cyclosporin A: a new drug in the field of canine dermatology. Vet Dermatol. 2004;15(2):61-74. doi:10.1111/j.1365-3164.2004.00376.x. 20. Data on file, Pet Owner Quantitative Market Research, 2013, Zoetis Inc. 21. Data on file, A Five-Year Post-Approval Safety Review for APOQUEL® in the US (May 2013 to August 2018), Zoetis Inc. 22. Volume 6C Summary of the Product Characteristics: SPC European Commission, Brussels. 1 Vol. 6C. July 10, 2006, 1-11. 23. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179. doi:10.1111/vde.12194. 24. Data on file, APOQUEL/CYTOPOINT Vet Tracker Wave 11, 2018, Zoetis Inc.25. Data on file, APOQUEL/CYTOPOINT Pet Tracker Wave 6, 2019, Zoetis Inc. 26. Data on file, APOQUEL Customer Survey, 2019, Zoetis Inc. 27. Data on file, APOQUEL Early Experience Program Pet Owner Aggregate Data, 2014, Zoetis Inc. 28. Data on file, Pet Owner Case Studies–Bijou, Nani, Gunner, Captain and Molly, Zoetis Inc.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2020 Zoetis Services LLC. All rights reserved. APQ-00371R4

CONTACT US

1-888-963-8471

We are Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2020 Zoetis Services LLC. All rights reserved.